Viking Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VKTX | SEPN | VRDN | GPCR | BHVN | MBX | |
|---|---|---|---|---|---|---|
| Market cap | 3.57B | 2.23B | 3.30B | 1.45B | 2.30B | 2.53B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -5.5 | -24.7 | -10.7 | -9.6 | -8.2 | -13.2 |
| Price/book | 6.1 | 5.7 | 6.8 | 1.1 | -23.4 | 6.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −24.95% | +154.68% | +5.65% | −39.17% | +78.66% | +112.13% |
| Today | +7.21% | +9.57% | +15.53% | +0.05% | −2.37% | −4.58% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VKTX news ›Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
Viking aims to enter the weight loss drug market. Viking aims to compete in a space dominated today by pharma giants Eli Lilly and Novo Nordisk. While I wouldn't expect Viking to oust these players from leadership, the company still could…
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech. Viking Therapeutics (VKTX -2.76%) received a new buy rating from UBS on Oct. 14, with analyst Joon Lee assigning the stock a 12-month…
Viking Therapeutics to Participate at Upcoming Investor Conferences
Nov 03, 2026, 16:30 ET Details of the company's participation are as follows: A live webcast of the Jefferies and Piper Sandler fireside chats may be accessed via a link on the Viking Therapeutics website in the Investors & Media section…
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Oct 28, 2026, 16:05 ET -- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study;…
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
By Zacks Equity Research, Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX). Viking Therapeutics…
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
Viking Therapeutics VKTX provided investors with an encouraging update during its third-quarter 2026 earnings call. During the Q&A session, CEO Brian Lian said the company was about 2.5 years away from a potential launch of its lead…
Viking Therapeutics: A Strong Injection, A Scaled-Back Pill
Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP agonist for obesity, with Phase 3 injection results expected in 2027. Read why VKTX stock is a hold. - Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP agonist for obesity,…
VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress
Viking Therapeutics, Inc. VKTX emphasized progress across its obesity pipeline during its third-quarter 2026 earnings call, highlighting the advancement of four Phase III trials evaluating injectable and oral VK2735. Viking Advances…
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)
The market felt that Viking had a chance of becoming the third company, after Eli Lilly ( LLY) and Novo Nordisk ( NVO ), to secure approval for a GLP-1 weight loss candidate and enter a market ... - Viking Therapeutics, Inc. is advancing…
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- fool.com8
- seekingalpha.com8
- theglobeandmail.com6
- 247wallst.com3
- marketscreener.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 44 articles, not a forecast.